Beneficial Ownership Report · SCHEDULE 13G
Electra Therapeutics, Inc.
ETRANASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Electra Therapeutics, Inc.
- Company CIK
- 0002088082
- Street
- 230 E. Grand Avenue
- Street (continued)
- Suite S-100
- City
- South San Francisco
- State / country code
- CA
- Postal code
- 94080
Statement details
- Security class
- Common Stock, $0.0001 par value per share
- Event date
- 09/21/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Redmile Group, LLC
- Citizenship / organization
- DE
- Reporting person type
- IA · OO
- Aggregate amount owned
- 5,462,881.00
- Percent of class
- 8.7
- Sole voting power
- 0.00
- Shared voting power
- 5,462,881.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 5,462,881.00
- Aggregate excludes certain shares
- N
- Comments
- The information in Item 4 relating to the shares of common stock, $0.0001 par value per share, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC and the calculation of the percent of such class of securities is incorporated by reference herein.
Reporting person 2
- Name
- Jeremy C. Green
- Citizenship / organization
- X0
- Reporting person type
- HC · IN
- Aggregate amount owned
- 5,462,881.00
- Percent of class
- 8.7
- Sole voting power
- 0.00
- Shared voting power
- 5,462,881.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 5,462,881.00
- Aggregate excludes certain shares
- N
- Comments
- The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy Green and the calculation of the percent of such class of securities is incorporated by reference herein.
Reporting person 3
- Name
- Redmile Biopharma Investments II, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 4,796,215.00
- Percent of class
- 7.6
- Sole voting power
- 0.00
- Shared voting power
- 4,796,215.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 4,796,215.00
- Aggregate excludes certain shares
- N
- Comments
- The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Redmile Biopharma Investments II, L.P. and the calculation of the percent of such class of securities is incorporated by reference herein.
Item 1
Issuer
Electra Therapeutics, Inc.
Principal executive office address
230 E. Grand Avenue Suite S-100 South San Francisco, CA 94080
Item 2
Citizenship
Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments II, L.P.: Delaware
Filing person
Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments II, L.P.
Principal business or residence address
Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments II, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939
Item 3
Not applicable indication
Y
Item 4
Percent of class
Redmile Group, LLC - 8.7% (3) Jeremy C. Green - 8.7% (3) Redmile Biopharma Investments II, L.P. - 7.6% (3)
Amount beneficially owned
Redmile Group, LLC - 5,462,881 (1) Jeremy C. Green - 5,462,881 (1) Redmile Biopharma Investments II, L.P. - 4,796,215 (2)
Sole voting power
Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments II, L.P. - 0
Shared voting power
Redmile Group, LLC - 5,462,881 (1) Jeremy C. Green - 5,462,881 (1) Redmile Biopharma Investments II, L.P. - 4,796,215 (2)
Sole dispositive power
Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments II, L.P. - 0
Shared dispositive power
Redmile Group, LLC - 5,462,881 (1) Jeremy C. Green - 5,462,881 (1) Redmile Biopharma Investments II, L.P. - 4,796,215 (2) (1) All of such shares of Common Stock are directly owned by certain investment vehicles, including Redmile Biopharma Investments II, L.P. ("RBI II"), for which Redmile is the investment manager (the "Redmile Funds"). Redmile may be deemed to beneficially own these securities in its capacity as their investment manager with discretion to vote and dispose of all shares of Common Stock held by the Redmile Funds. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any. (2) All of such shares of Common Stock are directly owned RBI II. (3) Percentage based on 62,766,955 shares of Common Stock outstanding immediately after the initial public offering, as reported in the Issuer's Prospectus dated September 17, 2026 filed with the SEC on September 18, 2026.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
N
Subsidiaries
See the response to Item 4.
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 99.1 - Joint Filing Agreement
Signature 1
- Reporting person
- Redmile Group, LLC
- Signed
- /s/ Jeremy C. Green
- Title
- Managing Member
- Date
- 09/28/2026
Signature 2
- Reporting person
- Jeremy C. Green
- Signed
- /s/ Jeremy C. Green
- Title
- Jeremy C. Green
- Date
- 09/28/2026
Signature 3
- Reporting person
- Redmile Biopharma Investments II, L.P.
- Signed
- /s/ Jeremy C. Green
- Title
- Managing Member of Redmile Group, LLC, Managing Member of Redmile Biopharma Investments II (GP), LLC, General Partner of Redmile Biopharma Investments
- Date
- 09/28/2026
Filed exhibits
- EX-99.1 ↗tm2626160d1_ex99-1.htm
Company context
We are a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. Our novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations, and increases upon activation to enable selective depletion of disease-driving cells while preserving normal immune function. By replacing broad immunosuppression with selective elimination of principal cells that drive disease, we believe our approach can do for immune-mediated diseases what precision oncology has done for cancer, transforming the treatment paradigm for patients. To our knowledge, we are the first company to advance this SIRP-targeted precision immune cell depletion approach into clinical development and demonstrate proof-of-concept in humans.